Caucasian

85% of Homeowners Worried Inflation Will Hurt Their Ability to Pay Mortgage

Retrieved on: 
Wednesday, April 12, 2023
Steps, ROI, Interest, Education, Caucasian, Home insurance, Real estate, Insurance, Credit, Brace

LOS ANGELES, April 12, 2023 /PRNewswire/ -- As economic uncertainty sweeps across the country, how worried are homeowners about making their mortgage payments? In the 2023 U.S. Mortgage Servicing Survey, digital mortgage-servicing platform Brace found out.

Key Points: 
  • LOS ANGELES, April 12, 2023 /PRNewswire/ -- As economic uncertainty sweeps across the country, how worried are homeowners about making their mortgage payments?
  • The overwhelming majority, 85%, said inflation makes them worry about their ability to pay their mortgages.
  • Nearly half (46%) of homeowners said the increased cost of living has already impacted their ability to pay their mortgages over the last three to six months.
  • Younger homeowners are especially worried about their ability to pay their mortgage, a reversal from historical trends.

Affordability Education Gap Is No. 1 Barrier to Increasing Independent and Gig Worker Health Coverage Rate, Per New Stride Health Survey

Retrieved on: 
Tuesday, November 15, 2022
Perception, SAN, Caucasian, Etsy, Health, Face, Uber, Tax, DoorDash, Freedom, Income, Grubhub, TaskRabbit, Allstate, Workforce, Stride Health, Patreon, Provisions of the Affordable Care Act, View, Mastercard, African Americans, Instacart, Multimedia, COVID-19, CEO, Public health, Inflation, Fidelity, Sentinel Capital Partners, National Queer Asian Pacific Islander Alliance, ACA, Hispanic, New Enterprise Associates, Health insurance, Rover, Venrock, Medicaid, Amazon

SAN FRANCISCO, Nov. 15, 2022 /PRNewswire/ -- Stride Health, the leader in portable benefits technology, today announced the release of new insights during the 2023 Open Enrollment period that demonstrate perceived affordability as the biggest barrier in getting independent and gig workers to enroll in healthcare coverage. The survey gathers information from more than 4,000 gig workers and digs into their perspective on healthcare, their finances and their outlook on work moving into 2023.

Key Points: 
  • "But there is a massive education gap around affordability among non-benefited worker populations where nearly six in ten uninsured workers think coverage is unaffordable and unattainable.
  • What does all of this mean for the more than 50 million (and growing) independent and gig workers who don't typically obtain coverage through an employer sponsored plan?
  • More than half of uninsured workers, on the other hand, cite affordability as the reason they don't have healthcare coverage.
  • The survey also digs into the financial outlook and satisfaction rates of workers, particularly independent and gig workers.

New Retrospective Data on African Americans with Advanced Symptomatic Sarcoidosis Treated with Acthar® Gel (Repository Corticotropin Injection) Presented at the American Thoracic Society Annual International Conference

Retrieved on: 
Tuesday, May 17, 2022
Consensus, Inflammation, Data analysis, Education, Sarcoidosis, European Respiratory Society, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, African Americans, Food, Foundation, Patient, Poster, Woman, Consensus decision-making, Adult, Research, FDA, Mallinckrodt, Data collection, Female, Conference, FSR, Comorbidity, Caucasian, ERS, Male, Diagnosis, Adrenocorticotropic hormone, Prevalence, CA, Pharmaceutical industry, Respiratory disease

DUBLIN , May 17, 2022 /PRNewswire/ -- Mallinckrodt plc, (OTCMKTS: MNKKQ) a global biopharmaceutical company, today announced results of a retrospective, observational medical chart review subgroup analysis assessing real-world treatment outcomes among African Americans with advanced symptomatic sarcoidosis who initiated therapy with Acthar Gel (repository corticotropin injection). Investigators presented the findings during a poster presentation at the American Thoracic Society Annual International Conference, taking place in San Francisco, CA. from May 13-18. The poster is available here on the company's website. The full study results, from which this subgroup analysis was pulled, were previously published in Therapeutic Advances in Respiratory Disease, an online, open-access peer-reviewed journal.

Key Points: 
  • Investigators presented the findings during a poster presentation at the American Thoracic Society Annual International Conference, taking place in San Francisco, CA.
  • Acthar Gel is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides.
  • The mean duration of Acthar Gel treatment was 31.7 weeks and 105 (62.5 percent) patients continued Acthar Gel therapy for at least six months.
  • To learn more about how sarcoidosis impacts African American women and FSR's #IgnoreNoMore Campaign sponsored by Mallinckrodt Pharmaceuticals, visit www.stopsarcoidosis.org/aaws-campaign/ .

Research Reveals Racial and Ethnic Disparities Persist in Pregnancy Outcomes of Patients with Lupus

Retrieved on: 
Monday, November 8, 2021
Magnet, Health, NIS, Lupus, Mortality, Weill Cornell Medicine, Pregnancy, U.S. News & World Report, SLE, Elective surgery, MD, 2009 Davis Cup, Education, News, Organization, Caucasian, Infection, Hospital, The Hospital, Rheumatology, MBBS, American Nurses Credentialing Center, Caesarean section, Healthcare Cost and Utilization Project, Hospital for Special Surgery, Kidney, Multimedia, Research, ACR, Woman, American College of Rheumatology, Patient, Laboratory, Therapy, Hispanic, African, Long Island, Nursing, HSS, African Americans, Physician, American College, Birth control

Further study is warranted to determine where resources are needed to improve access and care for these patients."

Key Points: 
  • Further study is warranted to determine where resources are needed to improve access and care for these patients."
  • In the new study, researchers used the National Inpatient Sample (NIS) to conduct a retrospective cross-sectional analysis of lupus and pregnancy related hospital admissions from 2008 to 2017.
  • The researchers evaluated the pregnancy outcomes of four groups: Caucasians, African Americans, Hispanics and Asians/Native Americans/Others.
  • "We have learned over the years that patients with lupus can become pregnant but need to do so in a certain way.

DiaMedica Therapeutics Announces Addition of Stroke Recurrence as a Second Independent Primary Endpoint in ReMEDy2 Phase 2/3 AIS Trial

Retrieved on: 
Monday, November 8, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Population, Urine, Safety, Obesity, Bleeding, Private Securities Litigation Reform Act, Hypertension, Form 10-K, Tissue, Therapy, Neurogenesis, U.S. Securities and Exchange Commission, Recurrence, Tobacco, Caucasian, Vascular dementia, Comorbidity, Survivor, Terminology, Ageing, Risk, Food, Inflammation, Lists of diseases, COVID-19, Stroke, DMAC, Chronic kidney disease, Remedy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Ischemia, TIA, Annual report, Company, Kidney, Retinopathy, SEC, Nature, Oxidative stress, Risk factor, AIS, Atrial fibrillation, Death, African Americans, MRS, KLK1, Fibrosis, Time, Diabetes, Nasdaq, Patient, FDA, Nitric oxide, Brain, Pharmaceutical industry, Medical device, DM199, Acute Ischemic Stroke and Stroke Recurrence, DiaMedica Therapeutics Inc., DM199, ACUTE ISCHEMIC STROKE AND STROKE RECURRENCE, DIAMEDICA THERAPEUTICS INC.

ReMEDy2 is a Phase 2/3 adaptive design, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of DM199 for the treatment of AIS, now addressing both stroke recovery and stroke recurrence.

Key Points: 
  • ReMEDy2 is a Phase 2/3 adaptive design, randomized, double-blind, placebo-controlled trial to evaluate the safety and efficacy of DM199 for the treatment of AIS, now addressing both stroke recovery and stroke recurrence.
  • Recurrent AIS will be evaluated based upon the proportion of patients who experience a recurrent AIS by Day 90.
  • The rationale for adding stroke recurrence to the ReMEDy2 trial as an independent primary endpoint is based on data obtained from DiaMedicas prior ReMEDy Phase 2 study in AIS.
  • Based upon our encouraging clinical experience in our Phase 2 study, we are very pleased to be formally elevating AIS recurrence to a primary endpoint in our ReMEDy2 study.

DiaMedica Therapeutics Initiates Pivotal Trial of DM199 for the Treatment of Acute Ischemic Stroke

Retrieved on: 
Monday, September 13, 2021
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Urine, Patient, Stroke, Form 10-K, Risk, Diabetes, KLK1, Annual report, Terminology, Caucasian, MRS, Neurology, Bleeding, Rankine scale, Nasdaq, Risk factor, Nitric oxide, Private Securities Litigation Reform Act, Remedy, TPA, Vascular dementia, COVID-19, Obesity, Neurogenesis, Tissue plasminogen activator, Therapy, TIA, FDA, Kidney, Plaque, Tissue, Ischemia, Ageing, Death, Brain, NIHSS, Chronic kidney disease, Recurrence, AIS, Nature, Survivor, Blood pressure, Emergency medicine, CKD, University, Retinopathy, Oxidative stress, DMAC, Trial of the century, Inflammation, Tobacco, Fibrosis, University of Pennsylvania, Lists of diseases, Atrial fibrillation, Hypertension, African Americans, Population, Pharmaceutical industry, Medical imaging, DM199, Acute Ischemic Stroke and Stroke Recurrence, DiaMedica Therapeutics Inc., DM199, ACUTE ISCHEMIC STROKE AND STROKE RECURRENCE, DIAMEDICA THERAPEUTICS INC.

The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.

Key Points: 
  • The ReMEDy2 Trial is a randomized, double-blind, placebo-controlled Phase 2/3 adaptive trial designed to enroll 350 patients at 75 sites in the United States.
  • DM199 is currently being studied in patients with acute ischemic stroke and chronic kidney disease.
  • DiaMedica Therapeutics Inc. is a clinical stage biopharmaceutical company committed to improving the lives of people suffering from serious diseases.
  • DiaMedicas lead candidate DM199 is the first pharmaceutically active recombinant (synthetic) form of the KLK1 protein, an established therapeutic modality for the treatment of acute ischemic stroke and chronic kidney disease.